Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 158

Sort by

Sort Order Select

Journal Articles

Health-Related Quality-of-Life Improvements after Exagamglogene Autotemcel in Patients with Severe Sickle Cell Disease

Akshay Sharma, Haydar Frangoul, Franco Locatelli, Kevin H.M. Kuo, Monica Bhatia, Markus Y Mapara, Michael J. Eckrich, Suzan Imren, Nanxin Li, Jaime Rubin, Siyu Zhang, Tina Liu, William Hobbs, Stephan A. Grupp

Blood (2024) 144 (Supplement 1): 7453.

https://doi.org/10.1182/blood-2024-204112

Published: 2024

Journal Articles

Impact of Current Manufacturing on Kymriah Real-World Effectiveness and Functional Persistence in Acute Lymphoblastic Leukemia (ALL) (KareALL): A Retrospective Study of Tisagenlecleucel (tisa-cel)-Treated Pediatric and Young Adult Patients (pts) with ALL

Rayne Rouce, J. Gregory Dolan, Christine L. Phillips, Muna Qayed, Michael A. Pulsipher, Lauren M. Vernau, Thomas J. Galletta, Sarah Votaw, Gabriela Llaurador Caraballo, Hongbo Yang, Yao Wang, Shashank Ghantoji, Mimi Tesfaye, Soyon Lee, Emer O'Sullivan, Stephan A. Grupp

Blood (2024) 144 (Supplement 1): 7724.

https://doi.org/10.1182/blood-2024-203376

Published: 2024

Journal Articles

In Vivo Persistence and Function of CAR19 T-Cell Products for Pediatric B-Cell Acute Lymphoblastic Leukemia Are Impacted By Media, Cytokine Supplementation and Metabolite Bioavailability during Ex Vivo Manufacturing

Blood (2024) 144 (Supplement 1): 3473.

https://doi.org/10.1182/blood-2024-210324

Published: 2024

Journal Articles

Cost-Effective Manufacture and Promising Initial Efficacy of huCART19 Cells Manufactured Using the Clinimacs Prodigy Platform

Allison Barz Leahy, Jennifer Brogdon, Lucy Cain, Amanda M. Dinofia, Joseph A. Fraietta, Richard Hanna, Stephan Kadauke, Raabia Khan, Yimei Li, Shannon L. Maude, Regina M. Myers, Laura Shinehouse, Anna Sparrow, Melissa Varghese, Lei Wang, Yongping Wang, Stephan A. Grupp

Blood (2024) 144 (Supplement 1): 3470.

https://doi.org/10.1182/blood-2024-204300

Published: 2024

Journal Articles

Preinfusion Risk Factors for the Development of Severe Immune Effector Cell Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T-Cell Infusion in Pediatric Patients

Caroline Diorio, Regina M. Myers, Yimei Li, Amanda M. Dinofia, Hongyan Liu, Allison Barz Leahy, Haley Newman, Jillian Dolan, Zachary Martinez, Amira Elhachimi, Cassidy Mullen, Alexander Lai Li, John Kim, David T. Teachey, Shannon L. Maude, Jennifer McGuire, Stephan A. Grupp

Blood (2024) 144 (Supplement 1): 3454.

https://doi.org/10.1182/blood-2024-204993

Published: 2024

Journal Articles

Durable Clinical Benefits with Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia

Blood (2024) 144 (Supplement 1): 512.

https://doi.org/10.1182/blood-2024-205779

Published: 2024

Journal Articles

TCL1A Is Associated with Blinatumomab Response and Immune Activation in Pediatric B-ALL

Blood (2024) 144 (Supplement 1): 634.

https://doi.org/10.1182/blood-2024-203756

Published: 2024

Journal Articles

Clinical Factors Associated with Prolonged Cytopenias after CD19 Chimeric Antigen Receptor T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia

Regina M. Myers, Yimei Li, Adam Lamble, Emily M. Hsieh, Samuel John, Gregory Dolan, Hongyan Liu, Lee Chen, Jennifer Sheppard, Amanda M. DiNofia, Colleen Annesley, Stephan A. Grupp, Deepa Bhojwani, Rebecca A. Gardner, Lia Gore, Susan R Rheingold, Nirali N. Shah, Michael A. Pulsipher

Blood (2024) 144 (Supplement 1): 4827.

https://doi.org/10.1182/blood-2024-202027

Published: 2024

Journal Articles

Durable Clinical Benefits with Exagamglogene Autotemcel for Severe Sickle Cell Disease

Blood (2024) 144 (Supplement 1): 4954.

https://doi.org/10.1182/blood-2024-204001

Published: 2024

Journal Articles

Quadriparesis and paraparesis following chimeric antigen receptor T-cell therapy in children and adolescents

Caroline Diorio, Laura Hernandez-Miyares, Diego A. Espinoza, Brenda L. Banwell, Amit Bar-Or, Amanda M. DiNofia, Allison Barz Leahy, Zachary Martinez, Regina M. Myers, Sarah E. Hopkins, Susan R. Rheingold, David T. Teachey, Angela N. Viaene, Lisa M. Wray, Shannon L. Maude, Stephan A. Grupp, Jennifer L. McGuire

Blood (2024) 144 (13): 1387–1398.

https://doi.org/10.1182/blood.2024023933

Published: 2024

Includes: Supplemental data

Journal Articles

Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD

Blood (2024) 144 (9): 1010–1021.

https://doi.org/10.1182/blood.2024025106

Published: 2024

Includes: Supplemental data

Journal Articles

Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy

Blood (2023) 141 (6): 609–619.

https://doi.org/10.1182/blood.2022017866

Published: 2023

Includes: Supplemental data

Journal Articles

CD22-Targeted CAR-Modified T-Cells Safely Induce Remissions in Children and Young Adults with Relapsed, CD19-Negative B-ALL after Treatment with CD19-Targeted CAR T-Cells

Blood (2022) 140 (Supplement 1): 2376–2377.

https://doi.org/10.1182/blood-2022-168139

Published: 2022

Journal Articles

Targeting CD38 in T-ALL Upregulates the Targetable Polyamine Metabolism Pathway

Caroline Diorio, Tiffaney L. Vincent, Tori Fuller, Rawan Shraim, Tina Glisovic-Aplenc, Theresa Ryan, Kimberly Veliz, Haley Newman, Gerald Wertheim, Hamid Bassiri, Annette Vu, Michael Hogarty, Carl H June, Stephan A. Grupp, Sarah K Tasian, Richard Aplenc, Saar Gill, David T. Teachey

Blood (2022) 140 (Supplement 1): 10285–10286.

https://doi.org/10.1182/blood-2022-167893

Published: 2022

Journal Articles

Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL

Blood (2022) 140 (6): 619–629.

https://doi.org/10.1182/blood.2022015825

Published: 2022

Includes: Supplemental data

Journal Articles

Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy

Allison Barz Leahy, Kaitlin J. Devine, Yimei Li, Hongyan Liu, Regina Myers, Amanda DiNofia, Lisa Wray, Susan R. Rheingold, Colleen Callahan, Diane Baniewicz, Maria Patino, Haley Newman, Stephen P. Hunger, Stephan A. Grupp, David M. Barrett, Shannon L. Maude

Blood (2022) 139 (14): 2173–2185.

https://doi.org/10.1182/blood.2021012727

Published: 2022

Includes: Supplemental data

Journal Articles

Ex Vivo T-Cell Receptor αβ + /CD19 + depletion of Peripheral Stem Cell Grafts for Pediatric Patients with Bone Marrow Failure (BMF) Undergoing Unrelated Donor Transplantation

Joseph H Oved, Caitlin W Elgarten, Yongping Wang, Stephan Kadauke, Dimitri S. Monos, David M. Barrett, Stephan A. Grupp, Nancy Bunin, Timothy S. Olson

Blood (2021) 138 (Supplement 1): 171.

https://doi.org/10.1182/blood-2021-154305

Published: 2021

Journal Articles

Comprehensive Secretome Profiling Elucidates Novel Disease Biology and Identifies Pre-Infusion Candidate Biomarkers to Predict the Development of Severe Cytokine Release Syndrome in Pediatric Patients Receiving CART19

Blood (2021) 138 (Supplement 1): 167.

https://doi.org/10.1182/blood-2021-149477

Published: 2021

Journal Articles

Complete Versus Incomplete Hematologic Recovery after CAR T Cell Therapy: Implications for Relapse Free Survival and Overall Survival in Pediatric and Young Adult Patients with Relapsed/Refractory B-ALL

Benjamin J Lerman, Yimei Li, Hongyan Liu, Regina M. Myers, Kaitlin Devine, Colleen Callahan, Diane Baniewicz, Stephan Kadauke, Amanda M. DiNofia, Susan R. Rheingold, Lisa Wray, Richard Aplenc, Stephan A. Grupp, Shannon L. Maude, Allison Barz Leahy

Blood (2021) 138 (Supplement 1): 1747.

https://doi.org/10.1182/blood-2021-151114

Published: 2021

Journal Articles

Repurposing Bi-Specific Chimeric Antigen Receptor (CAR) Approach to Enhance CAR T Cell Activity Against Low Antigen Density Tumors

Sherly Mardiana, Olga Shestova, Stephan A. Grupp, Marco Ruella, David M. Barrett, Saar Gill

Blood (2021) 138 (Supplement 1): 1727.

https://doi.org/10.1182/blood-2021-146995

Published: 2021

NARROW

Health-Related Quality-of-Life Improvements after Exagamglogene Autotemcel in Patients with Severe Sickle Cell Disease

Impact of Current Manufacturing on Kymriah Real-World Effectiveness and Functional Persistence in Acute Lymphoblastic Leukemia (ALL) (KareALL): A Retrospective Study of Tisagenlecleucel (tisa-cel)-Treated Pediatric and Young Adult Patients (pts) with ALL

In Vivo Persistence and Function of CAR19 T-Cell Products for Pediatric B-Cell Acute Lymphoblastic Leukemia Are Impacted By Media, Cytokine Supplementation and Metabolite Bioavailability during Ex Vivo Manufacturing

Cost-Effective Manufacture and Promising Initial Efficacy of huCART19 Cells Manufactured Using the Clinimacs Prodigy Platform

Preinfusion Risk Factors for the Development of Severe Immune Effector Cell Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T-Cell Infusion in Pediatric Patients

Durable Clinical Benefits with Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia

TCL1A Is Associated with Blinatumomab Response and Immune Activation in Pediatric B-ALL

Clinical Factors Associated with Prolonged Cytopenias after CD19 Chimeric Antigen Receptor T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia

Durable Clinical Benefits with Exagamglogene Autotemcel for Severe Sickle Cell Disease

Quadriparesis and paraparesis following chimeric antigen receptor T-cell therapy in children and adolescents

Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD

Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy

CD22-Targeted CAR-Modified T-Cells Safely Induce Remissions in Children and Young Adults with Relapsed, CD19-Negative B-ALL after Treatment with CD19-Targeted CAR T-Cells

Targeting CD38 in T-ALL Upregulates the Targetable Polyamine Metabolism Pathway

Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL

Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy

Ex Vivo T-Cell Receptor αβ + /CD19 + depletion of Peripheral Stem Cell Grafts for Pediatric Patients with Bone Marrow Failure (BMF) Undergoing Unrelated Donor Transplantation

Comprehensive Secretome Profiling Elucidates Novel Disease Biology and Identifies Pre-Infusion Candidate Biomarkers to Predict the Development of Severe Cytokine Release Syndrome in Pediatric Patients Receiving CART19

Complete Versus Incomplete Hematologic Recovery after CAR T Cell Therapy: Implications for Relapse Free Survival and Overall Survival in Pediatric and Young Adult Patients with Relapsed/Refractory B-ALL

Repurposing Bi-Specific Chimeric Antigen Receptor (CAR) Approach to Enhance CAR T Cell Activity Against Low Antigen Density Tumors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only